middle.news
How Arovella’s $21.9M War Chest Fuels ALA-101’s First Human Trial Launch
9:24am on Thursday 30th of October, 2025 AEDT
•
Biotechnology
Read Story
How Arovella’s $21.9M War Chest Fuels ALA-101’s First Human Trial Launch
9:24am on Thursday 30th of October, 2025 AEDT
Key Points
Cash reserves of $21.9 million support upcoming clinical milestones
Positive FDA Type D meeting de-risks IND application for ALA-101
SAPRO appointed as CRO for phase 1 dose escalation trial starting early 2026
US patent allowance granted for CAR-iNKT cell therapy platform
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Arovella Therapeutics (ASX:ALA)
OPEN ARTICLE